Saturday, August 16, 2025 8/16/2025

Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing

Award Number: R44TR005137
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing - ABSTRACT Cell and gene therapies have revolutionized treatment options for patients with pace of discovery and implementation accelerating. For example, clinical success of CAR-T cells for hematologic malignancies has led to use in expanded patient populations and trials targeting for other cancer types. While there are many cell therapies in preclinical development and clinical trials confidence in their successes is undermined by the inherent complexity of cells that remains difficult to decipher using existing tools. What is needed is an integrated analytical platform providing a matrix of readouts that reveal an in-depth real-time understanding of cell phenotype and metabolism. Such a platform will inform on the therapeutic potential before administration and by sampling patients will reveal aspects of cell behavior that correlate with efficacy. CellChorus is answering this need using our platform (“TIMING”) to undertake large scale single-cell analyses to track and characterize behavior of immune cells over time. TIMING uses sophisticated AI-based software, many years in development, to track and characterize behaviors of thousands of cells in parallel using time-lapse imaging. Multiple papers and repeat customers have helped validate our approach to commercialization. Based on users’ demand, we propose to advance TIMING by (i) developing and optimizing reagents and protocols to identify a suite of cell surface attributes, (ii) quantify proliferative capacity and (iii) determine metabolic activity before, during, and after cell-cell interactions. We will integrate these findings with our AI software to provide end users with a simple, unified assay system to run in their own laboratories on commercially available imaging instrumentation. The results of this project will be ready-to-use kits to reveal critical immune-biology of cells in critical and challenging environments. This is predicted to augment translational research and development leading to improvements in manufacturing and success in patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $984,242 )
2025	2025	CELLCHORUS INC	5000 GULF FWY RM 118	HOUSTON	TX	77204	HARRIS	USA	National Center for Advancing Translational Sciences	000	2	4/16/2025	EXTENSION WITH OR WITHOUT FUNDS	$984,242
														Subtotal = $984,242

Issue Date FY: 2024 ( Subtotal = $350,000 )
2024	2024	CELLCHORUS INC	5000 GULF FWY RM 118	HOUSTON	TX	77204	HARRIS	USA	National Center for Advancing Translational Sciences	000	1	4/30/2024	NEW	$350,000
														Subtotal = $350,000

Grand Total All Awards = $1,334,242

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing

Award Number: R44TR005137

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer